Navigation Links
Lotus Pharmaceuticals Raises $5 Million in Private Placement
Date:2/26/2008

t meet. Another portion of the Escrow Shares is being held in escrow subject to the Company listing on the NASDAQ Stock Market within 18 months following the Closing Date. Two-thirds of the Escrow Shares will be in escrow to ensure that the Purchasers receive their full redemption payments if they choose to redeem their Preferred Shares.

This transaction will be described in more detail in the Form 8-K and other supporting documents Lotus will file with the Securities and Exchange Commission.

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates Beijing Liang Fang Pharmaceutical Co., Ltd. ("Liangfang") and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. ("Enze") two Chinese pharmaceutical companies located in Beijing. Liangfang and Enze form a large comprehensive enterprise, which deals in an integration of the production, trade, sales and marketing of pharmaceuticals. Together, they possess some of the most advanced pharmaceutical-production equipment used in China, workshops authenticated by the National GMP, a suite of various medicines produced by Liangfang and/or Enze (together, "Lotus East"), and a number of high-tech personnel. Lotus East has business and office facilities of 2,000 square meters, a warehouse of 1,000 square meters and operates ten retail pharmacies in the Beijing area. Lotus East performs scientific research on new medicines, and the production, wholesale and retail sale of medicines. For more information, visit http://www.LotusEast.com .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "exp
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Lotus Blossom Consulting Announces E-Book on Infertility Treatment Financing
2. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...team develops device giving patients freedom of mo...DAY, July 26 (HealthDay News) -- An automated arti...e day be to dialysis patients what the insulin pum...rable artificial kidney (AWAK) works better than c...current issue of Clinical and Experimental Nephro...
(Date:7/25/2008)...AKE SUCCESS, N.Y., July 25 /PRNewswire-USNewswire/...as Chief Quality Officer and Vice President,of Str...monwealth Fund, a,national foundation committed to...e directed the foundation,s Program on Health Care...p://www.newscom.com/cgi-bin/prnh/20080725/DC28791L...
(Date:7/25/2008)...red immune response after antiretroviral therapy m... July 25 (HealthDay News) -- A new study challenge...(HCV) impairs the immune system,s ability to resto...ly active antiretroviral therapy (HAART). , Fro...ers are also infected with HCV. Intravenous drug u...
(Date:7/25/2008)...he Authority offers patients consumers tips and en...ient safety, HARRISBURG, Pa., July 25 /PRNewswire...thority today supports "National Patient Safety Da...s and their families to,participate fully in their...thing they can about their surgery or illness., "...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3
...ngton, in Seattle, a group of engineers has recent... latest creation: a surgical robot// to deploy in ... a remote control console. Military groups all ov... in remote surgery. On the battlefield, medical re...
...Children's Research Hospital have discovered that ...duction of a molecule that is key to the ability//...s to break down toxins, and of cells to extract en...estigators showed that ABCB6 is lodged within the ...
...ide rates among younger and older Americans have b...ling news: No one really knows why// . Those are ...t the University of South Carolina and released Th...tober issue of the American Journal of Public Heal...
...lty members performing microsurgery in Tanzania fr...om, or health care experts// in Vietnam presenting...thered in the Hopkins outpatient center. These are... Internet communication system that will be used f...
Other Medicine News:Health News:Doc at a Distance 2Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3Health News:High-Speed Internet2 Link Revolutionizes Global Medical Education 2
(Date:7/24/2008)... /PRNewswire-USNewswire/ -- Headlines claiming "so...e story. The small scale,preliminary study that D...duction, is based on recollected intake of soyfood...This study is confounded by many,issues, thus I fe...of,caution," warned Dr. Tammy Hedlund, a researche...
(Date:7/24/2008)...rance, July 24 /- NicOx S.A...ne results from the 52-week,open label safety exte...of,the 301 phase 3 study for naproxcinod. The resu...icacy was maintained for the one-year duration of,...essment scale. In,addition, the results showed tha...
(Date:7/23/2008)... /PRNewswire-USNewswire/ -- The following was,rele... Conyers, Ranking Member Smith, and Members of the...fy today., Since I appeared before this Committee...acquainted with the talented and dedicated profess... they do, and I have come to,appreciate that much ...
(Date:7/23/2008)...RNewswire-FirstCall/ -- Dendreon Corporation,(Nasd...dependent Data,Monitoring Committee (IDMC) to revi... survival relating to the Company,s Phase 3 IMPACT...ent, also known as D9902B) clinical trial,of PROVE...nvestigational,active cellular immunotherapy for t...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Steps toward Stopping Autoimmune Disease 1967 1Steps toward Stopping Autoimmune Disease 1967 2CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 1CeloNova BioSciences Announces Positive Results from European Study of Embozene 28TM 29 Microspheres for Treatment of Uterine Fibroids 1229 2Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 1Students Pursuing Health Care Careers Receive 2424 000 in Scholarships From National Hispanic Health Foundation 9799 2Solutions for Parents Who Need Cold Remedies for Their Children 9795 1Solutions for Parents Who Need Cold Remedies for Their Children 9795 2
...EGO, May 22, 2007 /PRNewswire/ -- A new study pres...iddle-of-the-night,balance, mobility or memory per...o placebo. This study also demonstrated, as in,pre... did have,impaired performances on these measures,...e-blind, placebo-controlled trial were,presented i...
... Release of Data for New Combination , , , , , P...cium channel blocker,amlodipine besylate with the ... produced significant mean reductions in,seated sy...th,hypertension, according to data presented at th...Second Annual Scientific Meeting and,Exposition (A...
Other Medicine Technology:New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 2New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 3New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon 4Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 2Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 3Amlodipine and Olmesartan Study Results Released;Late Breaker,Presented at American Society of Hypertension Twenty-Second Annual,Scientific Meeting (ASH 2007) 4
Meter Trax Control is a whole blood quality control that can be used for glucose, hemoglobin and hematocrit testing on point of care instruments.
Liquichek Qualitative Urine Toxicology Control is a liquid control designed for use with qualitative rapid urine drug screen panels, including Point of Care (POC) Drugs of Abuse (DOA) test kits like
Liquichek Sedimentation Rate Control is a bilevel human whole blood based control designed to monitor both manual and automated methods for measuring erythrocyte sedimentation rates.
Liquichek Hematology-16 Control is specifically designed for use on most hematology analyzers that measure up to 16 parameters and 3-part white blood cell differentials. This trilevel control can be
Medicine Products: